Trial site
IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena
ItalyNot linked to an institution yet
The trials here
What the 8 trials at this site are about, from their registry records.
- Phase
- Phase 26 trials
- Phase 32 trials
- Status
- Active, not recruiting3 trials
- Recruiting3 trials
- Not yet recruiting2 trials
- Lead sponsor
- Fondazione Ricerca Traslazionale2 trials
- Consorzio Oncotech1 trial
- Dizal Pharmaceutical Co. Ltd.1 trial
- IRCCS Istituto Nazionale Tumori Fondazione Pascale1 trial
- National Cancer Institute, Naples1 trial
- and 2 more
Running trials
Not yet recruiting
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study
2025-521583-35-00· Phase 2· Universita' Vita-salute S. Raffaele· Source
Active, not recruiting
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer
NCT05233982· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
2022-502959-54-00· Phase 3· Dizal Pharmaceutical Co. Ltd.· Source
Recruiting
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
NCT05817903· Phase 2· Consorzio Oncotech· Source
Recruiting
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
NCT05568212· Phase 2· Fondazione Ricerca Traslazionale· Source
Recruiting
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255471· Phase 3· National Cancer Institute, Naples· Source
Not yet recruiting
A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma positive for PD-L1 expression and germline or somatic mutations in the HRR genes
NCT04940637· Phase 2· Universita' Degli Studi Di Torino· Source
Recruiting
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations
NCT04811001· Phase 2· Fondazione Ricerca Traslazionale· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error